Human Longevity Inc

News

AstraZeneca has launched a new 'integrated genomics approach' to expand the genetic basis of its research, and aid drug discovery and development.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.